

Engagement Report for Clinical Commissioning Policies

Unique Reference Number	F05X02
Policy Title	Treatment of iron overload for transfused and non transfused patients with chronic inherited anaemias
Accountable Commissioner	Claire Foreman
Clinical Reference Group	Haemoglobinopathies CRG
Which stakeholders were contacted to be involved in policy development?	Haemoglobinopathies CRG membership and all registered stakeholders
Identify the relevant Royal College or Professional Society to the policy and indicate how they have been involved	Representatives of relevant Royal College or Professional Societies were contacted for Stakeholder Testing as part of the CRG
Which stakeholders have actually been involved?	All of the key stakeholders listed above were invited to comment
Explain reason if there is any difference from previous question	N/A
Identify any particular stakeholder organisations that may be key	None

For Public Consultation

to the policy development that you have approached that have yet to be engaged. Indicate why?	
How have stakeholders been involved? What engagement methods have been used?	<p>The draft policy was circulated to the full membership of the CRG (acting as PWG) and registered stakeholders for one week for their views, both to establish whether any amendments to the policy are required, and to understand from their perspective any issues for explorations during consultation.</p> <p>Two responses were received, one from a clinician and the other from a voluntary sector organisation. The responses requested</p> <ul style="list-style-type: none"> • Recognition that clinical and patient experience of treatment effectiveness can be different from that found in studies • The experience of children starting on chelation be considered • Further clarification of the section on MRI which was seen as confusing • Greater recognition in the policy of the difference in benefit between the treatment options for the management of cardiac / liver iron. The stakeholder noted this did not however affect the impact of the policy which is to commission all stated regimens where clinically appropriate.
What has happened or changed as a result of their input?	Stakeholders were invited to comment. No amendments were deemed necessary at this stage.
How are stakeholders being kept informed of progress with policy development as a result of their input?	This engagement report, along with the updated policy proposition will be circulated as part of the public consultation. Stakeholders will be notified and invited to comment further.
What level of wider public consultation is recommended by the CRG for the NPOC Board to agree as a result of stakeholder involvement?	30 day consultation recommended